Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Evaluating the Disease Modifying Potential of a Sleep Intervention on Alzheimer's Disease (AD) Biomarkers
Authors not listed
Natalie Denburg · 2019
Abstract
The study will examine whether 5mg melatonin (over the counter, OTC) over a 9-month period improves Alzheimer's disease (AD) biomarkers and cognitive function in two groups of individuals: those with mild cognitive impairment (MCI+) and those who are not (MCI-). AD biomarkers will be measured from cerebrospinal fluid (CSF) obtained from lumbar punctures. Cognitive function will be evaluated with routine neuropsychological tests.
AS OF AUGUST 2024, THE LUMBAR PUNCTURE PROCEDURES FOR THIS CLINICAL TRIAL HAVE BEEN ELIMINATED. THAT IS, PARTICIPANTS ARE NO LONGER RECEIVING A LUMBER PUNCTURE. BUT ARE CONTINUING TO RECEIVE TWO SEPARATE BLOOD DRAWS FOR BIOMARKER TESTING.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Anonymous. (2019). Evaluating the Disease Modifying Potential of a Sleep Intervention on Alzheimer's Disease (AD) Biomarkers. <em>Natalie Denburg</em>. https://clinicaltrials.gov/study/NCT03954899
Vancouver
Anonymous. Evaluating the Disease Modifying Potential of a Sleep Intervention on Alzheimer's Disease (AD) Biomarkers. Natalie Denburg. 2019.
BibTeX
@misc{anon2019Evalua,
title = {Evaluating the Disease Modifying Potential of a Sleep Intervention on Alzheimer's Disease (AD) Biomarkers},
author = {Anonymous},
journal = {Natalie Denburg},
year = {2019},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Chinese PLA General Hospital 2025
Open access · US-GOV
Ultra-high Field Multimodal and Multinuclear Neuroimaging Cohort Study of Alzheimer's Disease
The Lancet 2021
Preprint · OA
Alzheimer's disease
Handbook of clinical neurology 2019
Citation only
Alzheimer's disease
Neurobiology of Aging 2017
Open access · OA
Evaluating Alzheimer's disease biomarkers as mediators of age-related cognitive decline
University of California, Davis 2022
Open access · US-GOV
Proof of Mechanism Study of Senicapoc in Mild or Prodromal Alzheimer's Disease
Nature 2014
Preprint · OA